Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Iohexol
Drug ID BADD_D01180
Description Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Indications and Usage Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.
Marketing Status approved
ATC Code V08AB02
DrugBank ID DB01362
KEGG ID D01817
MeSH ID D007472
PubChem ID 3730
TTD Drug ID D02BLO
NDC Product Code 43228-100; 0407-1413; 71806-141; 0407-1414; 0407-1416; 0407-1415; 0407-1401; 0407-1411; 0407-1412; 65072-0801; 54702-501
UNII 4419T9MX03
Synonyms Iohexol | Iohexol 350 | Nycodenz | Compound 545 | Exypaque | Omnipaque
Chemical Information
Molecular Formula C19H26I3N3O9
CAS Registry Number 66108-95-0
SMILES CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thrombosis24.01.01.006---
Thyrotoxic crisis05.02.02.004; 06.09.04.004; 14.11.01.016; 19.07.03.0060.010670%-
Tinnitus04.04.01.002; 17.04.07.004--
Tongue disorder07.14.01.0020.021340%-
Tongue oedema07.14.02.007; 10.01.05.008; 23.04.01.0090.021340%-
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.0080.014227%
Tremor17.01.06.0020.304453%
Trismus15.05.04.004; 17.01.03.0040.010670%
Type I hypersensitivity10.01.03.0060.007113%-
Unresponsive to stimuli17.02.05.0310.117371%-
Urethral disorder20.07.01.002---
Urinary incontinence17.05.01.008; 20.02.02.0100.081804%
Urinary tract disorder20.08.01.001---
Urticaria10.01.06.001; 23.04.02.0014.764547%
Vein discolouration24.03.02.0040.007113%-
Venous thrombosis24.01.01.0080.007113%-
Ventricular fibrillation02.03.04.0080.071134%
Ventricular tachycardia02.03.04.0100.035567%
Vertigo04.04.01.003; 17.02.12.002--
Visual field defect06.02.07.003; 17.17.01.001---
Visual impairment06.02.10.013---
VIth nerve paralysis06.05.02.009; 17.04.02.002---
Vomiting07.01.07.0031.109688%
Vomiting projectile07.01.07.0120.046948%-
Wheezing22.03.01.0090.194907%
Withdrawal syndrome08.06.02.012; 19.07.06.023---
Yawning22.12.03.0370.014227%-
Infusion site erythema08.02.05.008; 12.07.05.009; 23.03.06.0160.015649%-
Acute generalised exanthematous pustulosis10.01.01.034; 11.07.01.018; 12.03.01.005; 23.03.10.0020.007113%-
Localised oedema02.05.04.006; 08.01.07.011; 14.05.06.0090.010670%
The 10th Page    First    Pre   10 11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene